Bayer Buys Into KRAS with $1.3bn Kumquat Deal

Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

Bayer buys into KRAS with $1.3bn Kumquat deal

Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat

Bayer to pay $1.3 billion for Kumquat cancer drug in pharma push

Bayer to help fund development of an early-stage medicine for several types of cancer

Bayer to Pay $1.3 Billion for Kumquat Cancer Drug in Pharma Push

Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its struggling pharma division’s growth prospects.

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering Bayer’s early precision oncology portfolio with a potential treatment for pancreatic, colorectal, and lung cancer, the companies said Tuesday. The collaboration comes after the FDA last month cleared Kumquat’s investigational new drug (IND) application…

Bayer deal caps big week for pancreatic cancer research

Bayer announces deal with Kumquat for a pancreatic cancer KRAS inhibitor, plus, promising mRNA vaccine research emerges from Phase 1 trial.